GNI Group Ltd.
Notice Regarding the Submission of Proxy Statement for Gyre Therapeutics’ Shareholders Meeting and Proposals Related to Issuance of Gyre Therapeutics Shares
Gyre Therapeutics plans to fully acquire Cullgen in Q2 2026 and will propose issuance of common shares upon conversion of Series B convertible preferred stock at the shareholders meeting.
Key Figures
- Gyre Therapeutics Common Stock Issuance Ratio: Up to 19.99% (Cap before shareholder approval)
- Gyre Therapeutics Annual Shareholders Meeting Date: June 10, 2026 (local time)
- Scheduled Completion of Cullgen Acquisition: Early Q2 2026
AI要約
Overview of M&A
Gyre Therapeutics, a consolidated subsidiary of GNI Group, Inc., will submit a proposal regarding the share exchange acquisition plan for the full acquisition of Cullgen Inc. at its annual shareholders meeting scheduled for June 10, 2026. Under the acquisition scheme, Cullgen shareholders will receive Gyre Therapeutics common shares and Series B convertible preferred shares, with the preferred shares convertible to common shares under certain conditions. Due to Nasdaq listing rules requiring shareholder approval for issuance exceeding 20% of common shares, the number of shares issued before approval will be limited to 19.99% or less.
Impact on Shareholders and Future Outlook
This acquisition proposal is subject to approval at Gyre Therapeutics’ annual shareholders meeting, and the impact on the Company's consolidated financial results is currently under review. Any changes or new disclosures related to this matter will be promptly announced. The acquisition completion is scheduled for early Q2 2026.
GNI Group, Inc.
Company overview · Stock price · Financial data · All IR
